Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact firstname.lastname@example.org.
Anti-Renal Fibrosis Effect of Urolithin B, Ellagitannin-Gut Microbial-Derived Metabolites, via TGF-β1/Smad and TLR4/NF-κb Signaling Pathways in a Rat Model of Unilateral Ureteral Obstruction
48 Pages Posted: 22 Jun 2019More...
Background: Urolithin B, gut microbiota metabolite of ellagitannins, contributes toward multiple health benefits attributed to ellagitannin-rich foods, has various bioactivities such as anti-inflammatory and anti-aging effects. This study was to investigate the effect of urolithin B on renal fibrosis and the underlying mechanism.
Methods: In vivo, unilateral ureteral obstruction (UUO) model was established with or without urolithin B treatment for three weeks. Then, changes in the kidney function and renal pathology were investigated. In vitro, the HK-2 cells were treated with TGF-β1 (10 ng/ml) for 24 h with or without urolithin B administration. Next cell damage and proliferation was evaluated.
Findings: In vivo, after urolithin B treatment, UUO-induced kidney injury was significantly ameliorated as shown by the improvement of renal function (BUN and serum creatinine), kidney morphology and the suppression of renal tubular injury markers of TGF-β1, Ang II, α-SMA and Col IV. Meanwhile, the renal inflammatory induced by UUO were also strikingly attenuated in urolithin B-treated rats (TNF-α, IL-6 and MCP-1). In vitro, urolithin B treatment markedly inhibited TGF-β1-induced HK-2 cells fibrosis and proliferation, suppressed TGF-β1 and NF-κB activation.
Interpretation: This works suggested that urolithin B contributes critically to the development of chronic kidney pathologies induced by UUO, and modulating TGF-β/Smad and TLR4/NF-κB signaling possibly represent a potential therapeutic strategy to impede renal fibrosis transition.
Funding: This work was supported by a grant from the National Natural Science Foundation of China (no. 31770381).
Declaration of Interest: The authors declare that there are no conflicts of interest.
Ethical Approval: All animal experiment were approved by the ethics committee of Wu Han University, Wu Han, China, and carried in accordance with National institutes of health guide for the care and use of laboratory animals.
Keywords: [comma separated]Urolithin B; Unilateral ureteral obstruction (UUO); TLR4/NF-кB pathway; TGF-β1/Smad pathway; inflammation
Suggested Citation: Suggested Citation